An mRNA for the SARS-CoV-2 Spike glycoprotein antigen (the prefusion stabilized variant, S-2P), stabilized against hydrolysis, for testing in COVID-19 mRNA vaccines.
This open source mRNA vaccine is being made available in the public domain to aid any efforts seeking to deliver COVID-19 mRNA vaccines in prefilled syringes without freezing.
The codons of this Superfolder S-2P mRNA have been redesigned to produce a highly stable mRNA structure predicted to have ~3x longer lifetime in (non-frozen) aqueous storage, based on computational design rules, algorithms, and a large corpus of experimental data developed through 2020 in the OpenVaccine project, based at Stanford University.
For avoidance of doubt, an Open Covid License is enclosed with this repository that grants license to any party for use of this sequence and enclosed data in research or product development that could accelerate the end of the COVID-19 pandemic.
> OpenVaccine Superfolder-v2 S-2P mRNA (Eterna 10646543, BugacMan's Deg-2_First_14nt_open)
AUGUUUGUUUUUUUAGUCCUCUUGCCGCUGGUUUCGAGUCAGUGCGUCAACCUUACGACGCGGACGCAGCUGCCGCCGGCCUACACGAACUCCUUCACGCGGGGGGUGUACUACCCCGACAAGGUGUUCCGCUCGUCUGUUCUGCACAGCACGCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGACAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCGACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUCGGUGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUACUCGUCCGCGAAUAAUUGUACGUUCGAGUAUGUGAGCCAGCCGUUCCUGAUGGAUCUUGAGGGCAAGCAGGGCAAUUUCAAGAAUUUGCGCGAGUUUGUCUUCAAGAACAUCGACGGCUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGAUCUCCCGCAGGGGUUCAGCGCGCUGGAGCCGCUGGUGGACCUGCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACCGGAGUUACCUGACGCCGGGUGACUCCAGUUCCGGGUGGACUGCGGGUGCCGCCGCGUACUACGUGGGGUACCUGCAGCCGCGGACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGGAUCUAUCAGACCUCCAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUCACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCCUCCGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACUUUCAAGUGUUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUACGCGGAUUCCUUCGUCAUCCGUGGGGACGAGGUCAGGCAGAUCGCGCCCGGGCAGACUGGGAAGAUAGCGGACUACAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUACCUGUACCGGCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGACAUUAGCACGGAGAUCUACCAGGCGGGUAGCACUCCGUGCAAUGGCGUGGAGGGCUUCAAUUGCUACUUUCCGCUGCAGUCGUACGGGUUUCAGCCCACCAACGGGGUGGGGUACCAGCCCUACCGCGUGGUGGUGCUGAGCUUCGAGCUCCUUCACGCGCCCGCGACGGUCUGUGGGCCCAAGAAGUCGACGAACUUAGUGAAGAACAAGUGCGUCAACUUCAACUUCAAUGGGCUCACGGGCACGGGGGUGCUGACGGAGUCGAACAAGAAGUUCCUGCCUUUCCAGCAGUUCGGGCGCGAUAUUGCCGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACGAGCAACCAGGUUGCCGUGUUGUACCAGGACGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUAUUUCAGACGCGGGCUGGUUGUCUGAUUGGUGCGGAGCACGUAAACAACUCCUAUGAGUGUGACAUACCCAUAGGAGCUGGCAUAUGUGCUUCGUACCAGACUCAGACAAACAGCCCGCGUCGAGCCCGGAGCGUUGCGUCGCAGAGCAUAAUCGCGUACACGAUGUCCCUCGGGGCGGAGAAUUCGGUGGCAUAUAGUAACAACAGUAUUGCCAUACCGACGAACUUCACGAUCUCCGUGACCACCGAGAUACUGCCGGUGAGCAUGACUAAGACGAGUGUAGACUGUACGAUGUAUAUCUGCGGCGACAGUACUGAGUGCAGUAACCUGUUGCUGCAGUAUGGGUCGUUCUGCACUCAGCUUAAUCGUGCUCUUACCGGGAUCGCCGUAGAGCAGGAUAAGAACACGCAGGAGGUCUUUGCGCAGGUGAAGCAGAUCUACAAGACUCCGCCUAUCAAGGACUUCGGCGGGUUCAACUUCAGCCAGAUUCUGCCAGACCCAUCUAAGCCGAGCAAGAGGUCCUUUAUUGAGGACCUCUUGUUCAACAAGGUGACUCUGGCAGAUGCUGGCUUUAUCAAGCAGUACGGCGAUUGUCUCGGGGACAUCGCUGCGCGCGAUUUGAUCUGUGCGCAAAAGUUCAACGGGCUCACUGUGCUACCACCUCUCCUGACGGACGAGAUGAUAGCACAGUAUACCAGCGCGCUGUUGGCUGGUACGAUCACUUCUGGUUGGACGUUCGGGGCGGGUGCGGCACUCCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGGUUCAACGGGAUCGGAGUGACGCAGAACGUCCUGUACGAAAACCAGAAGUUGAUCGCCAACCAGUUCAACAGCGCGAUUGGUAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAAGUUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUCCAGAUAGAUCGGCUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGCGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUCUGCGGGAAGGGGUAUCACCUGAUGUCCUUCCCGCAGAGCGCGCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCGAUAUGUCACGACGGGAAGGCGCACUUCCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCACUGGUUCGUCACGCAGCGCAACUUCUAUGAGCCGCAGAUAAUUACCACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUCGUGAACAACACGGUCUACGAUCCCCUGCAGCCCGAGCUGGAUAGUUUCAAGGAGGAGCUUGAUAAGUACUUCAAGAAUCAUACUUCCCCGGACGUGGAUCUUGGCGACAUUAGCGGGAUCAACGCUAGUGUCGUCAACAUCCAGAAGGAGAUCGACAGGCUCAAUGAGGUUGCGAAGAACCUCAACGAGAGCCUGAUCGAUCUCCAGGAGUUGGGGAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUCAUCGCGGGGCUGAUCGCGAUCGUGAUGGUCACGAUCAUGUUGUGCUGCAUGACGAGCUGCUGCUCCUGUUUGAAGGGCUGCUGCAGCUGCGGUUCGUGUUGUAAGUUUGACGAGGAUGACUCGGAGCCGGUGCUCAAGGGGGUGAAGCUGCACUACACGUGA
The RNA above also includes a stop codon. Feel free to copy/paste this sequence and use directly in your research or product development.
The above RNA has also been modified to code for the spike protein of the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) variants.
NOTE: v1.0.0 of this repository had a Delta variant superfolder whose sequence was incorrect.
> OpenVaccine Superfolder-v2 S-2P Alpha mRNA (H69-,V70-,Y144-,N501Y,A570D,D614G,P681H,T716I,S982A,D1118H, https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
AUGUUCGUGUUCCUCGUGCUCCUUCCGCUGGUCUCGAGCCAGUGCGUCAAUUUGACGACGAGGACGCAGUUGCCCCCCGCGUACACGAACUCGUUUACGCGGGGGGUGUACUACCCGGACAAGGUCUUCCGCAGCUCUGUCCUGCACAGCACUCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUUCGGGGACGAACGGGACGAAGAGGUUCGACAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCCACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUGGGUGUUUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUAUUCGUCCGCGAAUAAUUGUACCUUCGAGUAUGUCUCGCAGCCAUUCUUGAUGGAUCUUGAGGGCAAGCAGGGAAAUUUCAAGAAUCUCCGCGAGUUUGUCUUCAAGAACAUCGACGGGUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGAUCUCCCGCAGGGCUUCAGCGCUCUGGAGCCGCUGGUGGAUCUCCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACAGGAGUUACCUGACGCCGGGUGACUCCAGUAGUGGGUGGACUGCGGGUGCCGCGGCGUACUACGUCGGGUACCUGCAGCCGCGCACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGUAUCUAUCAGACCUCGAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUUACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCGAGUGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACGUUCAAGUGCUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUAUGCGGAUUCCUUCGUCAUCCGUGGUGACGAGGUGCGUCAGAUUGCGCCGGGGCAGACGGGGAAGAUAGCGGACUAUAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUAUCUUUACCGUCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGAUAUCUCGACCGAGAUCUACCAGGCCGGCUCGACGCCGUGCAACGGCGUCGAGGGGUUUAAUUGUUACUUUCCGUUACAGAGCUACGGGUUUCAGCCCACGUACGGGGUGGGGUACCAGCCCUACCGCGUCGUGGUGCUGAGCUUCGAGCUGCUGCACGCCCCGGCCACGGUGUGCGGUCCGAAGAAAAGUACAAACCUUGUGAAGAACAAGUGUGUGAACUUUAACUUCAACGGGCUCACCGGGACGGGGGUGUUGACGGAGAGUAACAAGAAGUUCCUGCCGUUCCAGCAGUUCGGUCGGGAUAUCGACGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACCAGCAACCAGGUUGCGGUGUUGUACCAGGACGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUCUUCCAGACUCGCGCGGGUUGCCUGAUUGGCGCUGAGCACGUGAACAACUCGUACGAGUGCGACAUUCCCAUUGGGGCGGGGAUCUGCGCGUCGUACCAGACCCAGACGAACAGCCACAGGCGGGCGAGGAGCGUCGCGUCGCAGUCGAUCAUCGCGUACACGAUGAGCCUGGGGGCGGAGAACAGUGUGGCCUAUUCGAACAACAGCAUAGCUAUCCCCAUCAAUUUUACGAUCAGUGUGACGACCGAGAUCUUGCCCGUGUCGAUGACCAAGACCUCGGUCGAUUGCACGAUGUACAUUUGUGGGGAUAGCACUGAGUGUUCUAACCUCCUGCUCCAGUACGGCAGUUUCUGUACGCAGCUCAACCGGGCGCUUACGGGGAUUGCCGUGGAGCAGGACAAGAACACUCAGGAGGUGUUUGCGCAGGUCAAGCAGAUCUACAAGACGCCUCCGAUCAAGGAUUUCGGGGGGUUCAAUUUCUCCCAGAUACUCCCCGACCCUUCGAAGCCCAGCAAGCGUAGCUUCAUUGAGGACCUGCUCUUCAAUAAGGUUACGCUUGCGGACGCGGGCUUCAUCAAGCAGUACGGGGACUGUCUGGGGGACAUUGCCGCCCGGGACCUGAUCUGUGCUCAGAAGUUCAAUGGGCUCACUGUUCUGCCGCCCCUGCUCACGGACGAGAUGAUCGCGCAGUACACGUCGGCGCUCCUCGCCGGCACGAUCACGUCGGGCUGGACGUUUGGGGCUGGUGCGGCGCUGCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGCUUCAAUGGGAUCGGGGUGACCCAGAAUGUCCUGUACGAGAAUCAGAAGCUCAUCGCCAAUCAGUUCAACUCGGCGAUCGGGAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAUCCUCGGUGCUGAACGAUAUUCUCGCGCGGCUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUAGACUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGUGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUUUGCGGGAAGGGCUAUCACCUGAUGUCCUUCCCGCAGUCCGCCCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCCAUAUGUCACGACGGGAAGGCCCACUUCCCCCGUGAGGGGGUCUUCGUGUCGAAUGGGACGCACUGGUUCGUGACGCAGCGGAAUUUCUAUGAGCCGCAGAUAAUUACGACUCACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUUGUUAACAACACCGUGUAUGAUCCCCUCCAGCCGGAGCUGGACAGCUUCAAGGAGGAGCUGGAUAAGUACUUCAAGAAUCACACGUCGCCGGACGUGGAUCUUGGGGACAUAUCGGGGAUCAACGCGAGUGUUGUUAACAUACAGAAGGAGAUCGACCGGCUCAAUGAGGUUGCGAAGAACCUCAAUGAGUCGUUGAUCGACCUUCAGGAGCUCGGCAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUUAUAGCGGGGCUGAUCGCCAUCGUGAUGGUGACGAUCAUGCUCUGCUGUAUGACGUCGUGCUGCAGCUGCCUCAAGGGCUGCUGCUCUUGCGGCAGCUGUUGCAAGUUCGACGAGGACGACUCCGAGCCUGUGCUGAAGGGGGUGAAGCUGCAUUAUACUUGA
> OpenVaccine Superfolder-v2 S-2P Beta mRNA (L18F,D80A,D215G,L242-,A243-,L244-,R246I,K417N,E484K,N501Y,D614G,A701V, https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1.full.pdf)
AUGUUCGUGUUCCUCGUGCUCCUUCCGCUGGUCUCGAGCCAGUGCGUCAAUUUCACGACGAGGACGCAGUUGCCCCCCGCGUACACGAACUCGUUUACGCGGGGGGUGUACUACCCGGACAAGGUCUUCCGCAGCUCUGUCCUGCACAGCACUCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGCGAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCCACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUGGGUGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUAUUCGUCCGCGAAUAAUUGUACCUUCGAGUAUGUCUCGCAGCCAUUCUUGAUGGAUCUUGAGGGCAAGCAGGGAAAUUUCAAGAAUCUCCGCGAGUUUGUCUUCAAGAACAUCGACGGGUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGGGCUCCCGCAGGGCUUCAGCGCUCUGGAGCCGCUGGUGGAUCUCCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCACAUCAGUUACCUGACGCCGGGUGACUCCAGUAGUGGGUGGACUGCGGGUGCCGCGGCGUACUACGUCGGGUACCUGCAGCCGCGCACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGUAUCUAUCAGACCUCGAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUUACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCGAGUGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACGUUCAAGUGCUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUAUGCGGAUUCCUUCGUCAUCCGUGGUGACGAGGUGCGUCAGAUUGCGCCGGGGCAGACGGGGAACAUAGCGGACUAUAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUAUCUUUACCGUCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGAUAUCUCGACCGAGAUCUACCAGGCCGGCUCGACGCCGUGCAACGGCGUCAAGGGGUUUAAUUGUUACUUUCCGUUACAGAGCUACGGGUUUCAGCCCACGUACGGGGUGGGGUACCAGCCCUACCGCGUCGUGGUGCUGAGCUUCGAGCUGCUGCACGCCCCGGCCACGGUGUGCGGUCCGAAGAAAAGUACAAACCUUGUGAAGAACAAGUGUGUGAACUUUAACUUCAACGGGCUCACCGGGACGGGGGUGUUGACGGAGAGUAACAAGAAGUUCCUGCCGUUCCAGCAGUUCGGUCGGGAUAUCGCGGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACCAGCAACCAGGUUGCGGUGUUGUACCAGGGCGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUCUUCCAGACUCGCGCGGGUUGCCUGAUUGGCGCUGAGCACGUGAACAACUCGUACGAGUGCGACAUUCCCAUUGGGGCGGGGAUCUGCGCGUCGUACCAGACCCAGACGAACAGCCCGAGGCGGGCGAGGAGCGUCGCGUCGCAGUCGAUCAUCGCGUACACGAUGAGCCUGGGGGUGGAGAACAGUGUGGCCUAUUCGAACAACAGCAUAGCUAUCCCCACGAAUUUUACGAUCAGUGUGACGACCGAGAUCUUGCCCGUGUCGAUGACCAAGACCUCGGUCGAUUGCACGAUGUACAUUUGUGGGGAUAGCACUGAGUGUUCUAACCUCCUGCUCCAGUACGGCAGUUUCUGUACGCAGCUCAACCGGGCGCUUACGGGGAUUGCCGUGGAGCAGGACAAGAACACUCAGGAGGUGUUUGCGCAGGUCAAGCAGAUCUACAAGACGCCUCCGAUCAAGGAUUUCGGGGGGUUCAAUUUCUCCCAGAUACUCCCCGACCCUUCGAAGCCCAGCAAGCGUAGCUUCAUUGAGGACCUGCUCUUCAAUAAGGUUACGCUUGCGGACGCGGGCUUCAUCAAGCAGUACGGGGACUGUCUGGGGGACAUUGCCGCCCGGGACCUGAUCUGUGCUCAGAAGUUCAAUGGGCUCACUGUUCUGCCGCCCCUGCUCACGGACGAGAUGAUCGCGCAGUACACGUCGGCGCUCCUCGCCGGCACGAUCACGUCGGGCUGGACGUUUGGGGCUGGUGCGGCGCUGCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGCUUCAAUGGGAUCGGGGUGACCCAGAAUGUCCUGUACGAGAAUCAGAAGCUCAUCGCCAAUCAGUUCAACUCGGCGAUCGGGAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAUCCUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUAGACUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGUGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUUUGCGGGAAGGGCUAUCACCUGAUGUCCUUCCCGCAGUCCGCCCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCCAUAUGUCACGACGGGAAGGCCCACUUCCCCCGUGAGGGGGUCUUCGUGUCGAAUGGGACGCACUGGUUCGUGACGCAGCGGAAUUUCUAUGAGCCGCAGAUAAUUACGACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUUGUUAACAACACCGUGUAUGAUCCCCUCCAGCCGGAGCUGGACAGCUUCAAGGAGGAGCUGGAUAAGUACUUCAAGAAUCACACGUCGCCGGACGUGGAUCUUGGGGACAUAUCGGGGAUCAACGCGAGUGUUGUUAACAUACAGAAGGAGAUCGACCGGCUCAAUGAGGUUGCGAAGAACCUCAAUGAGUCGUUGAUCGACCUUCAGGAGCUCGGCAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUUAUAGCGGGGCUGAUCGCCAUCGUGAUGGUGACGAUCAUGCUCUGCUGUAUGACGUCGUGCUGCAGCUGCCUCAAGGGCUGCUGCUCUUGCGGCAGCUGUUGCAAGUUCGACGAGGACGACUCCGAGCCUGUGCUGAAGGGGGUGAAGCUGCAUUAUACUUGA
> OpenVaccine Superfolder-v2 S-2P Gamma mRNA (L18F,T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,H655Y,T1027I, https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
AUGUUCGUGUUCCUCGUGCUCCUUCCGCUGGUCUCGAGCCAGUGCGUCAAUUUCACGAACAGGACGCAGUUGCCCUCGGCGUACACGAACUCGUUUACGCGGGGGGUGUACUACCCGGACAAGGUCUUCCGCAGCUCUGUCCUGCACAGCACUCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGACAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCCACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUUACCCGUUCCUGGGUGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUAUUCGUCCGCGAAUAAUUGUACCUUCGAGUAUGUCUCGCAGCCAUUCUUGAUGGAUCUUGAGGGCAAGCAGGGAAAUUUCAAGAAUCUCUCCGAGUUUGUCUUCAAGAACAUCGACGGGUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGAUCUCCCGCAGGGCUUCAGCGCUCUGGAGCCGCUGGUGGAUCUCCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACAGGAGUUACCUGACGCCGGGUGACUCCAGUAGUGGGUGGACUGCGGGUGCCGCGGCGUACUACGUCGGGUACCUGCAGCCGCGCACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGUAUCUAUCAGACCUCGAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUUACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCGAGUGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACGUUCAAGUGCUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUAUGCGGAUUCCUUCGUCAUCCGUGGUGACGAGGUGCGUCAGAUUGCGCCGGGGCAGACGGGGACCAUAGCGGACUAUAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUAUCUUUACCGUCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGAUAUCUCGACCGAGAUCUACCAGGCCGGCUCGACGCCGUGCAACGGCGUCAAGGGGUUUAAUUGUUACUUUCCGUUACAGAGCUACGGGUUUCAGCCCACGUACGGGGUGGGGUACCAGCCCUACCGCGUCGUGGUGCUGAGCUUCGAGCUGCUGCACGCCCCGGCCACGGUGUGCGGUCCGAAGAAAAGUACAAACCUUGUGAAGAACAAGUGUGUGAACUUUAACUUCAACGGGCUCACCGGGACGGGGGUGUUGACGGAGAGUAACAAGAAGUUCCUGCCGUUCCAGCAGUUCGGUCGGGAUAUCGCGGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACCAGCAACCAGGUUGCGGUGUUGUACCAGGACGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUCUUCCAGACUCGCGCGGGUUGCCUGAUUGGCGCUGAGUACGUGAACAACUCGUACGAGUGCGACAUUCCCAUUGGGGCGGGGAUCUGCGCGUCGUACCAGACCCAGACGAACAGCCCGAGGCGGGCGAGGAGCGUCGCGUCGCAGUCGAUCAUCGCGUACACGAUGAGCCUGGGGGCGGAGAACAGUGUGGCCUAUUCGAACAACAGCAUAGCUAUCCCCACGAAUUUUACGAUCAGUGUGACGACCGAGAUCUUGCCCGUGUCGAUGACCAAGACCUCGGUCGAUUGCACGAUGUACAUUUGUGGGGAUAGCACUGAGUGUUCUAACCUCCUGCUCCAGUACGGCAGUUUCUGUACGCAGCUCAACCGGGCGCUUACGGGGAUUGCCGUGGAGCAGGACAAGAACACUCAGGAGGUGUUUGCGCAGGUCAAGCAGAUCUACAAGACGCCUCCGAUCAAGGAUUUCGGGGGGUUCAAUUUCUCCCAGAUACUCCCCGACCCUUCGAAGCCCAGCAAGCGUAGCUUCAUUGAGGACCUGCUCUUCAAUAAGGUUACGCUUGCGGACGCGGGCUUCAUCAAGCAGUACGGGGACUGUCUGGGGGACAUUGCCGCCCGGGACCUGAUCUGUGCUCAGAAGUUCAAUGGGCUCACUGUUCUGCCGCCCCUGCUCACGGACGAGAUGAUCGCGCAGUACACGUCGGCGCUCCUCGCCGGCACGAUCACGUCGGGCUGGACGUUUGGGGCUGGUGCGGCGCUGCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGCUUCAAUGGGAUCGGGGUGACCCAGAAUGUCCUGUACGAGAAUCAGAAGCUCAUCGCCAAUCAGUUCAACUCGGCGAUCGGGAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAUCCUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUAGACUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGAUCAAGAUGAGUGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUUUGCGGGAAGGGCUAUCACCUGAUGUCCUUCCCGCAGUCCGCCCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCCAUAUGUCACGACGGGAAGGCCCACUUCCCCCGUGAGGGGGUCUUCGUGUCGAAUGGGACGCACUGGUUCGUGACGCAGCGGAAUUUCUAUGAGCCGCAGAUAAUUACGACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUUGUUAACAACACCGUGUAUGAUCCCCUCCAGCCGGAGCUGGACAGCUUCAAGGAGGAGCUGGAUAAGUACUUCAAGAAUCACACGUCGCCGGACGUGGAUCUUGGGGACAUAUCGGGGAUCAACGCGAGUGUUGUUAACAUACAGAAGGAGAUCGACCGGCUCAAUGAGGUUGCGAAGAACCUCAAUGAGUCGUUGAUCGACCUUCAGGAGCUCGGCAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUUAUAGCGGGGCUGAUCGCCAUCGUGAUGGUGACGAUCAUGCUCUGCUGUAUGACGUCGUGCUGCAGCUGCCUCAAGGGCUGCUGCUCUUGCGGCAGCUGUUGCAAGUUCGACGAGGACGACUCCGAGCCUGUGCUGAAGGGGGUGAAGCUGCAUUAUACUUGA
> OpenVaccine Superfolder-Delta mRNA (T19R,G142D,F157-,R158-,L452R,T478K,D614G,P681R,D950N, https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021)
AUGUUUGUUUUUUUAGUCCUCUUGCCGCUGGUUUCGAGUCAGUGCGUCAACCUUCGCACGCGGACGCAGCUGCCGCCGGCCUACACGAACUCCUUCACGCGGGGGGUGUACUACCCCGACAAGGUGUUCCGCUCGUCUGUUCUGCACAGCACGCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGACAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCGACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUCGACGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGGUGUACUCGUCCGCGAAUAAUUGUACGUUCGAGUAUGUGAGCCAGCCGUUCCUGAUGGAUCUUGAGGGCAAGCAGGGCAAUUUCAAGAAUUUGCGCGAGUUUGUCUUCAAGAACAUCGACGGCUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGAUCUCCCGCAGGGGUUCAGCGCGCUGGAGCCGCUGGUGGACCUGCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACCGGAGUUACCUGACGCCGGGUGACUCCAGUUCCGGGUGGACUGCGGGUGCCGCCGCGUACUACGUGGGGUACCUGCAGCCGCGGACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGGAUCUAUCAGACCUCCAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUCACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCCUCCGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACUUUCAAGUGUUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUACGCGGAUUCCUUCGUCAUCCGUGGGGACGAGGUCAGGCAGAUCGCGCCCGGGCAGACUGGGAAGAUAGCGGACUACAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUACCGGUACCGGCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGACAUUAGCACGGAGAUCUACCAGGCGGGUAGCAAGCCGUGCAAUGGCGUGGAGGGCUUCAAUUGCUACUUUCCGCUGCAGUCGUACGGGUUUCAGCCCACCAACGGGGUGGGGUACCAGCCCUACCGCGUGGUGGUGCUGAGCUUCGAGCUCCUUCACGCGCCCGCGACGGUCUGUGGGCCCAAGAAGUCGACGAACUUAGUGAAGAACAAGUGCGUCAACUUCAACUUCAAUGGGCUCACGGGCACGGGGGUGCUGACGGAGUCGAACAAGAAGUUCCUGCCUUUCCAGCAGUUCGGGCGCGAUAUUGCCGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACGAGCAACCAGGUUGCCGUGUUGUACCAGGGCGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUAUUUCAGACGCGGGCUGGUUGUCUGAUUGGUGCGGAGCACGUAAACAACUCCUAUGAGUGUGACAUACCCAUAGGAGCUGGCAUAUGUGCUUCGUACCAGACUCAGACAAACAGCCGGCGUCGAGCCCGGAGCGUUGCGUCGCAGAGCAUAAUCGCGUACACGAUGUCCCUCGGGGCGGAGAAUUCGGUGGCAUAUAGUAACAACAGUAUUGCCAUACCGACGAACUUCACGAUCUCCGUGACCACCGAGAUACUGCCGGUGAGCAUGACUAAGACGAGUGUAGACUGUACGAUGUAUAUCUGCGGCGACAGUACUGAGUGCAGUAACCUGUUGCUGCAGUAUGGGUCGUUCUGCACUCAGCUUAAUCGUGCUCUUACCGGGAUCGCCGUAGAGCAGGAUAAGAACACGCAGGAGGUCUUUGCGCAGGUGAAGCAGAUCUACAAGACUCCGCCUAUCAAGGACUUCGGCGGGUUCAACUUCAGCCAGAUUCUGCCAGACCCAUCUAAGCCGAGCAAGAGGUCCUUUAUUGAGGACCUCUUGUUCAACAAGGUGACUCUGGCAGAUGCUGGCUUUAUCAAGCAGUACGGCGAUUGUCUCGGGGACAUCGCUGCGCGCGAUUUGAUCUGUGCGCAAAAGUUCAACGGGCUCACUGUGCUACCACCUCUCCUGACGGACGAGAUGAUAGCACAGUAUACCAGCGCGCUGUUGGCUGGUACGAUCACUUCUGGUUGGACGUUCGGGGCGGGUGCGGCACUCCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGGUUCAACGGGAUCGGAGUGACGCAGAACGUCCUGUACGAAAACCAGAAGUUGAUCGCCAACCAGUUCAACAGCGCGAUUGGUAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGAACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAAGUUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUCCAGAUAGAUCGGCUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGCGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUCUGCGGGAAGGGGUAUCACCUGAUGUCCUUCCCGCAGAGCGCGCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCGAUAUGUCACGACGGGAAGGCGCACUUCCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCACUGGUUCGUCACGCAGCGCAACUUCUAUGAGCCGCAGAUAAUUACCACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUCGUGAACAACACGGUCUACGAUCCCCUGCAGCCCGAGCUGGAUAGUUUCAAGGAGGAGCUUGAUAAGUACUUCAAGAAUCAUACUUCCCCGGACGUGGAUCUUGGCGACAUUAGCGGGAUCAACGCUAGUGUCGUCAACAUCCAGAAGGAGAUCGACAGGCUCAAUGAGGUUGCGAAGAACCUCAACGAGAGCCUGAUCGAUCUCCAGGAGUUGGGGAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUCAUCGCGGGGCUGAUCGCGAUCGUGAUGGUCACGAUCAUGUUGUGCUGCAUGACGAGCUGCUGCUCCUGUUUGAAGGGCUGCUGCAGCUGCGGUUCGUGUUGUAAGUUUGACGAGGAUGACUCGGAGCCGGUGCUCAAGGGGGUGAAGCUGCACUACACGUGA
> OpenVaccine Superfolder-Delta-PSU mRNA stabilized for PSU (arnuvmodh, OpenVaccineVariantSprint2.0Fix mod Eli mjt arnuvmodh etc)
AUGUUUGUUUUUUUGGUUCUUCUGCCGUUGGUUUCGAGUCAGUGCGUUAAUUUGCGUACGCGGACGCAGUUGCCGCCGGCUUACACGAAUUCUUUUACGCGGGGGGUUUAUUACCCCGAUAAGGUGUUUCGUUCGUCUGUUUUGCACUCGACGCAGGAUCUUUUUCUCCCGUUUUUUUCCAACGUGACGUGGUUUCAUGCCAUUCAUGUUUCGGGGACGAACGGGACGAAGAGGUUUGAUAAUCCUGUUUUACCGUUUAACGACGGGGUUUAUUUUGCUUCGACGGAGAAGUCUAAUAUUAUUCGCGGGUGGAUUUUUGGGACCACUCUUGAUUCGAAGACUCAGUCUUUGUUGAUAGUGAACAAUGCUACGAACGUGGUUAUUAAGGUUUGUGAGUUUCAGUUCUGUAAUGACCCGUUUUUGGAUGUUUAUUAUCACAAGAACAAUAAGUCUUGGAUGGAGAGUGAGGUUUAUUCGUCCGCGAAUAAUUGUACUUUUGAGUAUGUUUCUCAGCCGUUUUUAAUGGAUCUUGAGGGUAAGCAGGGUAAUUUUAAGAAUUUGCGCGAGUUUGUUUUUAAGAACAUUGACGGUUAUUUUAAGAUUUAUUCGAAGCACACGCCGAUUAACCUUGUUCGUGAUUUGCCGCAGGGUUUUAGCGCUUUGGAGCCGCUUGUUGAUUUGCCGAUUGGUAUUAACAUUACGCGGUUUCAGACGCUUUUAGCUUUGCAUCGUUCGUAUUUGACGCCGGGGGAUUCUUCGAGUGGGUGGACUGCGGGUGCCGCGGCGUAUUACGUUGGGUAUUUGCAGCCGCGCACUUUUUUGCUUAAGUACAACGAGAAUGGUACGAUUACGGACGCGGUUGAUUGUGCGUUGGACCCUUUGUCGGAGACGAAGUGUACCCUUAAGUCGUUUACGGUGGAGAAGGGUAUUUAUCAGACUUCGAAUUUUCGGGUUCAGCCGACUGAGAGUAUUGUUCGGUUUCCGAAUAUUACGAACUUGUGUCCGUUUGGGGAGGUUUUCAACGCGACGCGGUUUGCUAGUGUGUACGCUUGGAAUCGGAAGAGGAUUUCGAAUUGUGUGGCGGAUUAUUCCGUUUUAUACAAUUCGGCUUCUUUUUCGACUUUUAAGUGUUACGGGGUGUCGCCUACGAAGUUGAACGACCUUUGUUUUACCAACGUUUAUGCGGAUUCUUUCGUUAUUCGUGGUGAUGAGGUGCGUCAGAUUGCUCCCGGUCAGACGGGUAAGAUAGCGGAUUAUAAUUAUAAGUUGCCCGACGAUUUUACGGGCUGCGUUAUUGCUUGGAAUAGCAAUAAUUUGGAUUCGAAGGUUGGGGGCAAUUAUAAUUACCGUUAUCGCUUGUUUCGGAAGAGCAAUUUGAAGCCUUUUGAGCGCGAUAUUUCGACCGAGAUUUAUCAGGCGGGGUCGAAGCCGUGUAACGGCGUCGAGGGGUUUAAUUGUUAUUUUCCGUUGCAGAGUUACGGGUUUCAGCCGACUAACGGGGUGGGGUAUCAGCCUUACCGCGUUGUUGUUUUGAGUUUCGAGCUUUUGCAUGCGCCCGCUACCGUUUGUGGGCCCAAGAAGUCGACGAAUUUAGUUAAGAAUAAGUGCGUUAAUUUUAACUUUAAUGGGCUUACCGGUACGGGCGUUUUAACGGAGAGUAAUAAGAAGUUUCUUCCUUUCCAGCAGUUUGGUCGGGAUAUUGCGGAUACUACGGAUGCGGUUAGGGAUCCGCAGACGCUUGAGAUUUUGGACAUUACGCCUUGCAGUUUCGGGGGCGUUAGUGUUAUUACGCCCGGUACGAAUACGAGUAACCAGGUUGCCGUUUUGUACCAGGGCGUUAAUUGUACUGAGGUUCCCGUUGCGAUUCAUGCGGAUCAGUUAACCCCGACGUGGAGGGUGUAUUCGACGGGGAGUAAUGUUUUUCAGACGCGCGCGGGUUGUUUGAUUGGCGCUGAGCAUGUGAAUAAUUCGUAUGAGUGCGAUAUUCCCAUUGGGGCGGGCAUUUGCGCGUCGUACCAGACCCAGACUAAUUCGAGGCGCCGGGCCAGGAGCGUUGCGUCGCAGAGCAUUAUUGCGUAUACGAUGAGUUUAGGGGCGGAGAACAGUGUGGCUUAUUCGAAUAAUUCUAUUGCUAUUCCCACGAAUUUUACGAUUAGUGUGACGACGGAGAUUUUGCCCGUUUCUAUGACCAAGACUUCCGUUGAUUGCACUAUGUAUAUUUGUGGGGAUAGCACGGAGUGUUCGAAUUUAUUAUUGCAGUACGGCAGUUUUUGUACGCAGCUCAAUAGGGCGCUUACGGGGAUUGCCGUAGAGCAGGAUAAGAAUACGCAGGAGGUGUUUGCGCAGGUCAAGCAGAUUUAUAAGACGCCUCCUAUUAAGGAUUUUGGGGGGUUUAAUUUUUCCCAGAUUUUGCCGGACCCUUCGAAGCCGAGCAAGCGUAGUUUUAUUGAGGAUUUACUUUUUAAUAAGGUUACGCUUGCGGAUGCCGGUUUUAUUAAGCAGUACGGCGAUUGUUUGGGGGAUAUUGCCGCCCGGGACCUUAUUUGUGCGCAGAAGUUCAAUGGGCUUACUGUUUUGCCGCCUUUACUUACGGACGAGAUGAUUGCUCAGUAUACGUCGGCGCUUUUGGCCGGGACGAUUACUUCGGGUUGGACGUUUGGGGCUGGUGCGGCGUUGCAGAUUCCGUUUGCUAUGCAGAUGGCGUACCGUUUUAAUGGGAUCGGCGUUACGCAGAACGUGCUUUACGAAAAUCAGAAGCUUAUUGCCAAUCAAUUUAAUUCGGCGAUCGGGAAGAUUCAGGAUUCUUUGUCGAGUACGGCUUCCGCGUUGGGGAAGCUGCAGAACGUGGUGAACCAGAAUGCUCAGGCUCUUAAUACGUUGGUGAAGCAGUUGUCGUCCAAUUUUGGGGCGAUUUCUUCGGUGUUGAACGAUAUUCUUAGUCGGUUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUCGUCUUAUUACUGGUCGUUUGCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUUAGGGCUGCUGAGAUACGUGCGUCUGCGAAUUUAGCGGCGACCAAGAUGAGCGAGUGCGUUUUGGGGCAGAGUAAGCGGGUGGAUUUUUGCGGGAAGGGUUAUCAUUUGAUGUCUUUUCCGCAGAGUGCGCCUCACGGGGUCGUUUUUUUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCCAUUUGUCACGACGGGAAGGCGCAUUUUCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCAUUGGUUUGUGACGCAGCGUAAUUUUUAUGAGCCGCAGAUAAUUACCACUGAUAAUACUUUUGUUAGUGGUAAUUGUGAUGUGGUUAUAGGGAUUGUUAACAACACGGUUUAUGAUCCUUUGCAGCCCGAGUUGGAUAGUUUUAAGGAGGAGCUUGAUAAGUAUUUUAAGAAUCAUACUUCGCCGGACGUUGAUUUGGGGGAUAUUUCCGGGAUUAACGCUUCGGUUGUUAACAUUCAGAAGGAGAUUGAUAGGCUUAAUGAGGUUGCUAAGAACCUUAAUGAGUCUUUAAUUGACCUUCAGGAGUUGGGGAAGUAUGAGCAGUACAUUAAGUGGCCUUGGUACAUUUGGCUCGGUUUUAUUGCGGGGUUGAUUGCGAUUGUGAUGGUGACGAUUAUGUUGUGUUGCAUGACCAGUUGUUGUUCUUGUUUGAAGGGCUGCUGCAGUUGCGGUUCGUGUUGUAAGUUUGACGAGGACGAUUCGGAGCCGGUGCUGAAGGGCGUUAAGCUCCAUUAUACUUAG
> OpenVaccine Superfolder-Omicron mRNA (Eterna 11151255, BugacMan, AK m69.1 mod mod)
AUGUUUGUGUUCUUGGUCCUCUUGCCGCUGGUUUCGAGUCAGUGCGUGAACUUGACGACGCGGACGCAGCUGCCGCCGGCCUACACGAACUCCUUCACGCGGGGGGUGUACUACCCCGACAAGGUGUUCCGCUCGUCUGUUCUGCACAGCACGCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUCACGUGGUUCCACGUGAUUUCGGGGACGAACGGGACGAAGAGGUUCGAUAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGAUAGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUCGUGAACAACGCGACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUGGAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUAUUCGUCCGCGAAUAAUUGUACCUUCGAGUAUGUCUCGCAGCCAUUCUUGAUGGAUCUUGAGGGCAAGCAGGGGAACUUCAAGAACUUGAGGGAGUUUGUCUUCAAGAACAUCGACGGGUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAUCGUCCGCGAGCCGGAGGAUCUCCCGCAGGGCUUCAGCGCUCUGGAGCCGCUGGUGGACCUGCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACCGGAGUUACCUGACGCCGGGUGACUCCAGUAGUGGGUGGACUGCGGGUGCCGCGGCGUACUACGUCGGGUACCUGCAGCCGCGCACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGUAUCUAUCAGACCUCGAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUUACGAACCUGUGUCCGUUCGACGAGGUCUUCAACGCGACGCGGUUCGCUAGUGUGUACGCUUGGAACAGGAAGCGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUUGGCUCCGUUUUUUACGUUCAAGUGCUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUAUGCGGACUCGUUCGUGAUCCGUGGUGACGAGGUGCGUCAGAUUGCUCCCGGGCAGACGGGCAACAUAGCGGACUACAAUUAUAAGUUGCCCGACGACUUUACGGGCUGCGUGAUCGCGUGGAACUCCAACAAGUUGGACUCGAAGGUGUCGGGCAACUAUAAUUACCUCUAUCGCCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGAUAUCUCGACCGAGAUCUACCAGGCGGGGAACAAGCCGUGCAACGGCGUGGCGGGGUUUAAUUGUUACUUUCCGUUGCGGAGCUACAGCUUCCGGCCCACCUACGGGGUGGGGCACCAGCCCUACCGCGUGGUGGUGCUGAGCUUCGAGCUGCUGCACGCCCCGGCCACCGUGUGCGGCCCGAAGAAAAGCACGAACUUAGUGAAGAACAAGUGCGUGAACUUUAACUUCAACGGGCUGAAGGGGACCGGGGUGUUGACGGAGAGUAACAAGAAGUUCCUUCCCUUCCAGCAGUUCGGUCGGGAUAUCGCGGACACCACGGACGCGGUGCGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACCCCCGGUACGAACACCAGCAACCAGGUUGCGGUGUUGUACCAGGGGGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUCUUCCAGACUCGCGCGGGUUGCCUGAUUGGCGCUGAGUACGUGAACAACUCGUACGAGUGCGACAUCCCGAUUGGGGCGGGGAUCUGCGCGUCGUACCAGACCCAGACGAAGUCGCACCGGAGGGCCAGGAGCGUGGCGUCGCAGUCGAUCAUCGCGUACACGAUGAGCCUGGGGGCGGAGAACAGUGUGGCCUAUUCGAACAACUCGAUCGCGAUCCCCACGAAUUUUACGAUCAGUGUGACCACCGAGAUCUUGCCCGUGUCGAUGACCAAGACCUCGGUGGAUUGCACGAUGUACAUUUGUGGGGAUUCGACCGAGUGUUCGAAUUUGCUCCUGCAGUACGGCAGUUUCUGUACGCAGCUCAAGCGGGCGCUUACGGGGAUUGCCGUAGAGCAGGACAAGAACACGCAGGAGGUGUUUGCGCAGGUCAAGCAGAUCUACAAGACGCCUCCGAUCAAGUACUUUGGCGGGUUCAAUUUCUCCCAGAUACUCCCCGACCCUUCGAAGCCCAGCAAGCGUAGCUUUAUUGAGGACCUGCUCUUCAAUAAGGUUACGCUUGCGGACGCGGGCUUCAUCAAGCAGUACGGGGACUGUCUGGGGGACAUUGCCGCCAGGGACUUGAUCUGCGCGCAGAAGUUCAAGGGGCUCACUGUUCUGCCGCCCCUGCUCACGGACGAGAUGAUCGCGCAGUACACGUCGGCGCUCCUGGCCGGUACGAUUACUUCCGGGUGGACGUUUGGGGCUGGUGCGGCGCUGCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGCUUCAACGGGAUCGGCGUGACGCAGAACGUGCUGUACGAGAAUCAGAAGCUCAUCGCCAAUCAGUUCAACUCGGCGAUCGGGAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCACAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAAGUUCGGGGCGAUAUCCUCGGUGCUGAACGAUAUUUUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUCGCCUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGCGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUCUGCGGGAAGGGGUAUCACCUGAUGUCCUUCCCGCAAAGCGCGCCUCACGGGGUGGUGUUUCUCCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACGACUGCGCCGGCCAUAUGUCACGAUGGGAAGGCGCACUUCCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCACUGGUUCGUCACGCAGCGCAACUUCUAUGAGCCGCAGAUAAUUACCACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUCGUGAACAACACGGUCUACGAUCCCCUGCAGCCCGAGCUGGAUAGUUUCAAGGAGGAGCUUGAUAAGUACUUCAAGAAUCAUACUUCGCCGGACGUUGAUCUCGGGGACAUCUCCGGGAUCAACGCUUCGGUGGUCAACAUCCAGAAGGAGAUCGACCGGCUCAAUGAGGUUGCGAAGAACCUCAAUGAGUCGUUGAUCGACCUUCAGGAGUUAGGCAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUCAUCGCGGGGCUGAUCGCGAUCGUGAUGGUCACGAUCAUGUUGUGCUGCAUGACGAGCUGCUGCUCCUGUUUGAAGGGCUGCUGCAGCUGCGGUUCGUGUUGCAAGUUCGACGAGGACGACUCGGAGCCGGUGCUCAAGGGGGUCAAGCUGCACUACACGUGA
> OpenVaccine Superfolder-Omicron-PSU mRNA (Eterna 11151699, Rivalium, Rivalium_RLT-2b 0.5554 PSU Degscore)
AUGUUUGUUUUUUUGGUCCUUUUACCGUUGGUUUCGAGUCAGUGCGUUAAUCUUACGACGCGGACGCAGUUGCCCCCGGCUUACACGAAUUCUUUUACGCGGGGGGUGUAUUACCCCGAUAAGGUGUUUCGUUCGUCUGUUUUGCACAGUACGCAGGAUCUUUUUCUCCCGUUUUUUUCGAAUGUGACGUGGUUUCACGUUAUUUCGGGGACGAACGGGACGAAGAGGUUUGAUAACCCCGUUUUACCGUUUAACGACGGGGUGUAUUUUGCUUCGAUAGAGAAGUCUAAUAUAAUUCGGGGGUGGAUUUUUGGCACUACUUUGGAUUCGAAGACUCAGUCUUUACUUAUAGUCAAUAAUGCGACGAAUGUUGUUAUUAAGGUUUGUGAGUUCCAGUUUUGUAAUGAUCCAUUUUUGGAUCAUAAGAAUAACAAGAGUUGGAUGGAGUCUGAGUUUCGGGUUUAUAGUAGUGCCAAUAAUUGCACUUUUGAGUAUGUUUCGCAGCCGUUUUUGAUGGAUCUUGAGGGCAAGCAGGGCAAUUUUAAGAAUUUGCGCGAGUUUGUUUUUAAGAACAUUGACGGUUACUUUAAGAUUUAUUCGAAGCACACGCCGAUUAUUGUUCGUGAGCCGGAGGAUUUGCCGCAGGGUUUUAGCGCUUUGGAGCCGCUUGUUGAUUUGCCGAUUGGCAUUAACAUUACGCGGUUUCAGACGCUUUUAGCUUUGCACCGGAGUUAUUUGACUCCGGGCGAUUCUUCGAGUGGGUGGACUGCGGGUGCCGCGGCGUAUUACGUCGGGUAUUUGCAGCCGCGCACUUUUUUAUUGAAGUACAAUGAGAACGGCACGAUCACUGAUGCGGUUGAUUGUGCUUUGGAUCCUUUAUCGGAGACGAAGUGCACCCUUAAGUCGUUUACGGUGGAGAAGGGGAUUUAUCAGACUUCGAAUUUUCGGGUUCAGCCGACUGAGAGUAUUGUUCGGUUUCCGAACAUUACGAACUUGUGUCCGUUUGACGAGGUGUUUAACGCGACGCGGUUUGCUAGUGUUUACGCUUGGAAUAGGAAGCGGAUUUCGAAUUGUGUGGCGGAUUAUUCCGUUUUAUACAAUUUGGCUCCGUUUUUUACUUUUAAGUGUUACGGGGUGUCGCCUACGAAGUUGAACGACCUUUGUUUUACCAACGUUUAUGCGGAUUCUUUCGUUAUUCGUGGUGACGAGGUGCGUCAGAUUGCUCCCGGUCAGACGGGUAAUAUUGCGGAUUAUAAUUAUAAGUUGCCGGAUGAUUUUACGGGUUGCGUUAUUGCUUGGAAUAGUAAUAAGCUUGAUUCGAAGGUUUCCGGCAAUUAUAAUUACCUUUAUCGCUUGUUUAGGAAGAGCAAUUUGAAGCCUUUUGAGCGCGAUAUUUCGACCGAAAUUUAUCAGGCUGGUAAUAAGCCUUGUAAUGGGGUGGCGGGUUUCAAUUGUUAUUUUCCGUUGAGGUCGUAUUCUUUUCGGCCCACGUACGGGGUUGGGCAUCAGCCGUAUCGGGUGGUAGUUUUAUCGUUUGAGCUGUUGCAUGCGCCGGCUACUGUUUGUGGGCCGAAGAAGAGUACGAACUUGGUUAAGAAUAAGUGCGUUAAUUUUAAUUUUAAUGGGUUGAAGGGGACGGGCGUUCUUACGGAGAGUAAUAAGAAGUUUUUGCCGUUUCAGCAGUUUGGUCGGGAUAUUGCCGAUACUACGGAUGCGGUUAGGGAUCCGCAGACGCUUGAGAUUUUGGACAUUACGCCUUGCAGUUUCGGGGGCGUUAGUGUUAUUACGCCCGGUACGAAUACGAGCAACCAGGUUGCCGUUUUGUACCAGGGCGUUAAUUGUACUGAGGUUCCCGUUGCGAUUCAUGCGGAUCAGUUAACCCCGACGUGGAGGGUGUAUUCGACGGGGAGUAAUGUUUUUCAGACGAGGGCCGGGUGUUUAAUUGGGGCGGAGUACGUAAAUAAUUCUUAUGAGUGCGACAUUCCUAUUGGGGCGGGCAUUUGCGCGUCGUACCAGACCCAGACGAAGUCUCAUCGUCGGGCCAGGAGCGUUGCGUCGCAGAGCAUUAUUGCGUAUACGAUGAGUUUGGGGGCGGAGAACAGUGUGGCUUAUUCGAAUAAUUCUAUUGCUAUUCCCACGAAUUUUACUAUUAGUGUGACGACGGAGAUUUUGCCCGUUUCUAUGACCAAGACUUCCGUUGAUUGCACUAUGUAUAUUUGUGGGGAUAGCACGGAGUGUUCGAACUUACUUUUGCAGUACGGCAGUUUUUGUACGCAGCUCAAGCGGGCGCUUACGGGGAUUGCCGUGGAGCAGGAUAAGAAUACUCAGGAGGUGUUUGCGCAGGUCAAGCAGAUUUAUAAGACGCCUCCUAUUAAGUAUUUUGGGGGGUUUAAUUUUUCCCAGAUUUUGCCGGACCCUUCGAAGCCGAGCAAGCGUAGUUUUAUUGAGGAUUUACUUUUUAAUAAGGUUACGCUUGCGGAUGCCGGUUUUAUUAAGCAGUACGGCGAUUGUUUGGGGGAUAUUGCCGCCCGGGAUCUUAUUUGUGCGCAGAAGUUUAAGGGGCUUACUGUUUUGCCGCCUUUACUUACGGACGAGAUGAUUGCUCAGUAUACGUCGGCGCUUUUGGCCGGGACGAUUACUUCCGGUUGGACGUUUGGGGCUGGUGCGGCGUUGCAGAUUCCGUUUGCUAUGCAGAUGGCGUACCGUUUUAAUGGGAUUGGCGUUACUCAGAAUGUUUUGUAUGAGAAUCAGAAGCUGAUUGCUAACCAGUUUAAUUCGGCCAUUGGGAAGAUUCAGGAUUCUUUGUCGAGUACGGCUUCCGCGUUGGGGAAGUUGCAGGACGUGGUGAAUCAUAAUGCUCAGGCUCUUAAUACGUUGGUGAAGCAGUUGUCGUCCAAGUUUGGGGCGAUUUCGUCGGUGUUGAACGAUAUUUUUAGUCGGUUGGACCCGCCGGAGGCGGAGGUUCAGAUCGAUCGUCUUAUUACUGGUCGUUUGCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUUAGGGCUGCUGAGAUACGUGCGUCUGCGAAUUUAGCGGCGACCAAGAUGAGCGAGUGCGUUUUGGGGCAGAGUAAGCGGGUGGAUUUUUGCGGGAAGGGUUAUCAUUUGAUGUCUUUUCCGCAGAGUGCGCCUCACGGGGUUGUUUUUUUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAAUUUCACCACGGCGCCGGCCAUUUGUCACGACGGGAAGGCGCAUUUUCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCAUUGGUUUGUGACGCAGCGUAAUUUUUAUGAGCCGCAGAUAAUUACCACUGAUAAUACUUUUGUUAGUGGUAAUUGUGAUGUGGUUAUAGGGAUUGUUAACAACACGGUUUAUGAUCCUUUGCAGCCCGAGUUGGAUAGUUUUAAGGAGGAGCUUGAUAAGUAUUUUAAGAAUCAUACUUCCCCGGACGUUGAUUUGGGGGAUAUUUCCGGGAUUAACGCUUCGGUUGUUAACAUUCAGAAGGAGAUUGAUAGGCUUAAUGAGGUUGCUAAGAACCUUAAUGAGUCUUUAAUUGACCUUCAGGAGUUGGGGAAGUAUGAGCAGUACAUUAAGUGGCCUUGGUACAUUUGGCUCGGUUUUAUUGCGGGGUUGAUUGCGAUUGUGAUGGUGACGAUUAUGUUGUGUUGCAUGACCAGUUGUUGUUCUUGUUUGAAGGGCUGUUGCAGUUGCGGUUCGUGUUGUAAGUUUGACGAGGACGAUUCGGAGCCGGUGCUUAAGGGGGUUAAACUUCAUUAUACUUAG
Here is a visualization of the secondary structure of the mRNA, as well as the Superfolder-Delta-PSU, compared to the secondary structure of a mRNA designed through codon optimization:
Secondary structure visualization of Superfolder-Omicron:
Secondary structure visualization of Superfolder-Omicron-PSU:
ViennaRNA MFE predicted secondary structures, visualized in RiboGraphViz, colored by DegScore (Leppek, 2021, bioRxiv).
The below exact amino acid sequence is the basis for most mRNA vaccines that have been tested and deployed at the time of writing.
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant. 1273 amino acids.
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
For ongoing efforts to create new vaccines for new variants, we are also providing sequences that have been adapted to code for the spike protein of strains B.1.351, B.1.1.7, P.1, B.1.617.2, and B.1.1.529 that were designed using the mRNA hotfix tool.
NOTE: v1.0.0 of this repository had a Delta variant superfolder whose sequence was incorrect.
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain B.1.1.7. 1270 amino acids.
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIDDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPINFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILARLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTHNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain B.1.351. 1270 amino acids.
MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain P.1. 1273 amino acids.
MFVFLVLLPLVSSQCVNFTNRTQLPSAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNYPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLSEFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGTIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAAIKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain B.1.617.2 (Delta). 1271 amino acids.
MFVFLVLLPLVSSQCVNLRTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKNNKSWMESEVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSRRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQNVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain B.1.1.529 (Omicron). 1270 amino acids.
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
The sequence was designed through the following steps, which have been validated through extensive experiments on model mRNA's by the Das and Barna labs at Stanford University (OpenVaccine consortium, 2021, in prep).
Superfolder-Delta-PSU
and Superfolder-Omicron-PSU
-- were designed based on predictions for stabilization incurred by using Pseudouridine instead of Uracil (Leppek, 2021).Find more details and a comparison to other design methods here.
Kozak M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes (1990). Proc Natl Acad Sci U S A. 87(21):8301-5. doi: 10.1073/pnas.87.21.8301
Leppek, K., Byeon, G.W., Kladwang, W., Wayment-Steele, H.K., Kerr, C., ... Barna, M., Das, R. (2021). Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. https://www.biorxiv.org/content/10.1101/2021.03.29.437587v1.
Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, Bukur V, Kuhn AN, Türeci Ö, Sahin U. (2018), Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. Mol Ther. 27(4):824-836. doi: 10.1016/j.ymthe.2018.12.011
Wayment-Steele, H.K., Kim, D.S., Choe, C.A., Nicol, J.J., Wellington-Oguri, R., Sperberg, R.A.P., Huang, P., Eterna Participants, Das, R. (2020). Theoretical basis for stabilizing messenger RNA through secondary structure design. bioRxiv, 262931. doi:10.1101/2020.08.22.262931
Wayment-Steele, H.K., Kladwang, W., Eterna Participants, Das, R. (2020). RNA secondary structure packages ranked and improved by high-throughput experiments. bioRxiv, 124511. 10.1101/2020.05.29.124511
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020). LinearDesign: Efficient Algorithms for Optimized mRNA Sequence Design. arXiv preprint arXiv:2004.10177
For answers to any additional questions that might help accelerate the end of the COVID-19 pandemic, please contact Rhiju Das, Stanford University, rhiju@stanford.edu.